Performing Clinical Trials on Cannabinoid Products with Jeff Chen, MD

Dr. Jeff Chen is the Co-founder and CEO of Radicle Science, a health tech company generating history's first dataset and AI to prove and predict the effects of health and wellness products.  Previously, he was the Founder and Exec Director of the UCLA Cannabis Research Initiative.



At CannMed 2022, Dr. Chen presented results for Radicle Health’s ACES study, a randomized clinical trial, involving 13 CBD products and 3,000 participants. The project was possible thanks to Radicle Science’s unique, virtual approach to clinical trials, which removes many challenges that make them expensive and difficult to conduct. 



Topics covered during the conversation include: 



The many challenges associated with performing clinical trials on cannabinoids How a virtual, direct-to-consumer approach overcomes many of those challenges The value brands, manufacturers, and distributors get from clinical trial data Results from the ACES Study, the largest randomized CBD clinical trial in history How Radicle applied lessons learned from ACES study to design the Radicle Spectrum study  Other minor cannabinoids that Radicle Science is investigating and which have the most therapeutic potential 



Thanks to This Episode's Sponsor: Planetarie



Female-founded Planetarie is truly plant-based wellness designed to keep you moving and playing. Planetarie created a water-based, hemp extraction method and built a vertically integrated company with USDA-organic certified products made from that full-spectrum stable CBDa. The answer for plant-based anti-inflammation is found in Nature, beautifully harnessed with science.



Learn more at planetarie.com



Additional Resources



Results of Radicle Science’s ACES Study: Largest Randomized Trial of CBD in History - CannMed 2022 PresentationRadicle Science WebsiteReview the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study